Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response.
Mei Y, Wang X, Zhang J, Liu D, He J, Huang C, Liao J, Wang Y, Feng Y, Li H, Liu X, Chen L, Yi W, Chen X, Bai HM, Wang X, Li Y, Wang L, Liang Z, Ren X, Qiu L, Hui Y, Zhang Q, Leng Q, Chen J, Jia G.
Mei Y, et al. Among authors: wang x, wang l, wang y.
Nat Cancer. 2023 Sep;4(9):1273-1291. doi: 10.1038/s43018-023-00598-9. Epub 2023 Jul 17.
Nat Cancer. 2023.
PMID: 37460871